Botulinum antitoxin for UKHSA's stockpile comes from Emergent BioSolutions
- UK Health Security Agency
- Competitive flexible procedure, 1 bid
- 16 November 2026 to 15 November 2028
UK Health Security Agency (UKHSA) is buying Botulinum Antitoxin Heptavalent (HBAT) from Emergent BioSolutions Canada Inc. The supply will support national health security stockpiling.
Before the tender, UKHSA asked suppliers about the products available, pack sizes and minimum order quantities. Commercial terms counted for 80% of the score, with social value and technical risk at 10% each.
One bid came in. The award was made in October 2026 without a published value, and the two-year contract can be extended to November 2030.
Contract ends November 2028
- What
- Medicines supply
- Supplier
- Emergent BioSolutions Canada Inc
- Value
- Not published
- How it was bought
- Competitive flexible procedure
- 1 bid
- Dates and next
- Nov 2026 to Nov 2028
- Option to Nov 2030